Feedback

Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization

Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Schönharting, Wolfgang;
Affiliation
Interdisziplinäres Onkologisches Zentrum (IOZ), 80336 Munich, Germany
Roehnisch, Tim;
Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Manoochehri, Mehdi;
ORCID
0000-0003-4369-3591
Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Christoph, Jan;
ORCID
0009-0005-6845-6148
Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Sieger, Marie;
Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Nogueira, Mauro;
ORCID
0000-0002-0825-8650
Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Martos-Contreras, Mari Carmen;
Affiliation
PMCR GmbH, 76135 Karlsruhe, Germany
Kunz, Meik

Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). The epitopes were predicted using our in-house bioinformatic pipeline, and the immunogenicity was tested by IFN-γ ELISPOT and intracellular cytokine staining assays. In total, a significant peptide-specific T-cell response was detected against 18 out of the 76 (≈24%) tested peptides. The patient’s follow-up by measuring serologic markers showed a significant reduction in the tumor marker levels following BITAP immunization. Along with standard treatment, the patient treated with the BITAP showed stable disease with a remarkably improved overall survival, and no serious treatment-related adverse effects. In conclusion, our findings suggest that BITAP immunization is feasible, and safe, and may induce tumor regressions in patients with HER2-positive subsets of breast cancer.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2023 by the authors.

Use and reproduction: